O. Ø. Thomsen

Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease

K. Bendtzen, C. Steenholdt, J. Brynskov, 2012, Alimentary pharmacology & therapeutics.

Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease – subgroup results from a placebo‐controlled study

S. Hanauer, I. Lawrance, W. Sandborn, 2011, Alimentary pharmacology & therapeutics.